IQGAP1 and neoplasm: A cell-penetrating derivative of the IQGAP1 WW domain was first developed by Jameson et al. [12], who showed that this peptide inhibited the proliferation, migration, viability and tumor-forming ability of breast, colorectal and melanoma tumor cells that contained activating mutations in the RAS/MAPK pathway.